Nicotinamide (Standard)

Nicotinamide (Standard)

• CAS Number: 98-92-0
• UNSPSC Description: Nicotinamide (Standard) is the analytical standard of Nicotinamide. This product is intended for research and analytical applications. Nicotinamide is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide also inhibits SIRT1. Nicotinamide increases cellular NAD+, ATP, ROS levels. Nicotinamide inhibits tumor growth and improves survival. Nicotinamide also has anti-HBV activity[1][2][3][4].
• Target Antigen: Endogenous Metabolite; Sirtuin
• Type: Reference Standards
• Related Pathways: Cell Cycle/DNA Damage;Epigenetics;Metabolic Enzyme/Protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/nicotinamide-standard.html
• Purity: 99.85
• Smiles: O=C(C1=CC=CN=C1)N
• Molecular Weight: 122.127
• References & Citations: Sci Adv. 2024 Jun 21;10(25):eadj8650.|Aging Cell. 2021 Oct 3;e13491.|Am J Cancer Res. 2023 Feb 28.|Am J Physiol Heart Circ Physiol. 2021 Aug 1;321(2):H353-H368.|Autophagy. 2020 Oct;16(10):1823-1837.|bioRxiv. 2020 Mar.|bioRxiv. 2023 Jun 6.|Br J Haematol. 2024 Oct 15.|Cancer Cell. 2024 Oct 14;42(10):1729-1746.e8.|Cancer Lett. 2024 Jun 14:597:217005.|Cardiovasc Toxicol. 2022 Aug 20.|Cell Death Differ. 2023 Oct 12.|Cell Death Dis. 2021 Sep 23;12(10):865.|Cell Death Discov. 2022 May 17;8(1):265.|Cell Discov. 2024 Sep 17;10(1):96.|Cell Prolif. 2024 Apr 16:e13646.|Cell Signal. 2024 Sep 5:111386.|Cell Stem Cell. 2022 Sep 1;29(9):1366-1381.e9.|Circ Res. 2022 Aug 19;131(5):456-472.|Commun Biol. 2023 Mar 2;6(1):235.|Ecotoxicol Environ Saf. 2024 Jul 18:282:116733.|EMBO J. 2020 Sep 15;39(18):e104365.|Exp Cell Res. 27 October 2022, 113404.|Hum Reprod. 2019 Jul 8;34(7):1186-1194.|Hum Reprod. 2020 Mar 27;35(3):494-503. |Int Immunopharmacol. 2023 May 13;120:110279.|Int J Biol Macromol. 2024 Jul 27:134120.|Int J Mol Sci. 2022 Aug 12;23(16):9049.|iScience. 2024 Aug 21;27(9):110775.|J Exp Clin Cancer Res. 2023 Jan 5;42(1):5.|J Ginseng Res. 15 February 2022.|J Immunol. 2022 Jul 18;ji2200078.|J Mol Cell Cardiol. 29 October 2022.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|J Proteomics. 2023 Mar 24;104889.|J Proteomics. 2024 May 24:105213.|Nat Commun. 2021 Jul 9;12(1):4227.|Nat Commun. 2021 Sep 20;12(1):5548.|Nat Commun. 2023 Sep 22;14(1):5917.|Nat Genet. 2023 Nov 20.|Oncogene. 2020 Mar;39(11):2437-2449. |Oncogene. 2024 Sep 10.|Oxid Med Cell Longev. 2021 Jan 19;2021:6610543.|Patent. US20180263995A1.|PeerJ. 2023 May 11.|PLoS Pathog. 2024 Mar 12;20(3):e1012082.|Research Square Preprint. 2022 Feb.|SSRN. 2024 May 30.|Theranostics. 2019 Apr 13;9(9):2424-2438.|Theriogenology. 2020 Dec;158:233-238.
• Shipping Conditions: Room Temperature
• Storage Conditions: 4°C (Powder, sealed storage, away from moisture and light)
• Clinical Information: No Development Reported